New technologies to avoid cervical cancer misdiagnosis
Data from regions of the world show that human papilloma virus prevalence tends to be highest in women younger than 35 years, and then peaks again in women over 45 years of age
Learning objectives
- To understand the epidemiology and burden of cervical cancer on the African continent and in South Africa
- To understand the global challenges associated with cervical cancer screening
- To interpret the successes and limitations of Pap smear technology
- To clinically use HPV DNA and mRNA molecular testing for cervical cancer screening
- To recognise the importance of accurate screening and detection of high-risk HPV subtypes
- To use p16 and Ki-67 biomarker technology to improve accuracy of cervical cancer screening and triage patients accordingly
- To understand the advantages of new technologies such as CINtec ® PLUS cytology as a dual-stain triage tool for p16 and Ki-67 biomarkers
- To interpret the HPV test as a first-line diagnostic and screening tool with the added capabilities of dual-biomarker technologies such as CINtec® PLUS cytology.
To access this module, please register or login: